Effect of Dietary Cholesterol and Niacin Supplementation on Serum Enzymatic Alterations in Experimentally Induced Renal Dysfunction in Wistar Rats

Pallavi Khajuria*, Pratiksha Raghuwanshi, Aditi Lal Koul, Ankur Rastogi, Sumeet Kour and Vishav Pratap Singh

Division of Veterinary Physiology and Biochemistry, Sher-e-Kashmir University of Agricultural Sciences and Technology, F. V.Sc. & A.H., SKUAST-J, R.S. Pura, Jammu, INDIA

*Corresponding author: P Khajuria; Email: pallavi.khajuria@yahoo.com

Received: 19 April, 2018
Revised: 26 June, 2018
Accepted: 29 June, 2018

ABSTRACT

Study was carried out to evaluate the effect of dietary cholesterol and niacin supplementation and renal dysfunction in wistar rats. Eighty-four adult healthy wistar male rats were divided into twelve equal groups. Experiment was carried out as per 2 × 3 × 2 factorial design with two clinical conditions (Kidney-Normal and Kidney-Compromised); three levels of cholesterol supplementation (0%, 0.5% and 1.0%) and two niacin levels (unsupplemented and supplemented @ 100 mg/kg body weight), respectively. At the start of the experiment, renal dysfunction was induced in respective rats by daily injection of gentamicin for 8 days. Blood samples were collected from experimental animals on zero, 20th, 40th and 60th days of trial to study liver specific serum enzyme profile viz. aspartate amino transaminase (AST), alanine amino transaminase (ALT), alkaline phosphatase (ALP) and acid phosphatase (ACP). Gentamicin injection resulted in significantly increase in levels of enzymes. Also cholesterol supplementation @ 0.5% and 1% resulted in significantly higher levels of enzymes studied. However, treatment with niacin @ 100 mg/kg body weight resulted in marked improvement in level of enzymes studied.

Keywords: Gentamicin, renal dysfunction, niacin, Wistar rats

Kidneys perform various functions in the body such as osmoregulation, excretion of end products including urea and creatinine, synthesis of hormones such as rennin and erythropoietin and for the metabolism of vitamin D. Thus, the kidneys maintain water and electrolyte balance as well as pH to regulate metabolic activities. To perform their function well, the kidneys have the richest blood supply per unit weight of tissue in the body. Renal arteries supply blood supply to kidneys and venous drainage is performed by the renal veins. There are many environmental contaminants and chemical variables such as drugs, alter the functions of the kidney (Mahmood and Waters, 1994).

Nephrotoxicity is characterized by any adverse functional or structural change in the kidney due to the effect of various chemical and biological products, that is inhaled, ingested or absorbed or which yields metabolite with an identifiable toxic effect on the kidney (Aslam et al., 2013). Drug induced nephrotoxicity is an important cause of renal failure. Nephrotoxic drugs include antiretrovirals (example, tenofovir), antimicrobials (example, aminoglycosides) and chemotherapeutic agents (example, cisplatin) (Perazella, 2009). Aminoglycosides including gentamicin are potential agents for the treatment of gram negative bacterial infections. Nephrotoxicity is the major side effect of aminoglycosides, which accounts for about 10-15% of all cases of acute renal failure (Homes and Weinberg, 1986). The specificity of gentamicin renal toxicity is apparently related to its preferential accumulation in the renal convoluted tubules and its effect on biological membranes. The excretion of gentamicin is through kidneys without degradation and about 5-10 % is concentrated in the proximal convoluted tube, highly exceeding serum levels (Costa et al., 1987). Aminoglycosides have highly basic charge and thus they poorly penetrate cell membranes (Erdem et al., 2000). The
proximal tubular cells of the renal cortex have a greater ability to concentrate aminoglycosides several folds more than plasma levels (Erdem et al., 2000).

Cholesterol is the most abundant steroid in the body. Far from being harmful, when properly regulated, it is a critically important molecule as an integral component of cellular membranes where it helps in maintenance of membrane structural integrity and fluidity. Cholesterol homeostasis in the body is maintained by the balance between cholesterol biosynthesis, and its metabolism. Additionally it also serves as precursor for several important biomolecules such as steroid hormones, bile acids, and vitamin D. Hypercholesterolemia is well-known to be an independent risk factor for renal injury (Oda and Keane, 1999) and to aggravate the pathogenesis of a variety of clinical and experimental renal diseases (Stulak et al., 2001). Several studies indicated that abnormalities in lipid metabolism can often accompany and exacerbate renal disease (Vazquez-Perez et al., 2001). Hypercholesterolemia is well-known to be an independent risk factor for renal injury (Oda and Keane, 1999) and to aggravate the pathogenesis of a variety of clinical and experimental renal diseases. There are many evidences that supports the fact that high cholesterol diet exacerbates kidney damage in animal models of kidney disease (Mori and Hirano, 2012). Previous data showed that even a short exposure to high cholesterol diet supplementation is associated with an increase in oxidative stress and renal inflammation (Wilson et al., 2003). Liver enzymes such as AST, ALT, ACP and ALP are marker enzymes for assessing liver function and integrity (Kim et al., 2006). These enzymes are usually elevated in acute hepatotoxicity or mild hepatocellular injury (Kim et al., 2006).

Chronic kidney disease results in profound alterations in lipid metabolism and plasma lipid profiles characterized by hypertriglyceridemia, diminished HDL cholesterol, impaired HDL maturation, and depressed HDL antioxidant and anti-inflammatory activities (Vaziri, 2006). Nephrotic syndrome is also found to be associated with profound dysregulation of lipid/lipoprotein metabolism, severe hyperlipidemia, and lipiduria. Common features of dyslipidemia in nephritic syndrome are hypercholesterolemia, increased plasma low-density lipoprotein (LDL), impaired LDL and high-density lipoprotein (HDL) clearance, and depressed maturation of HDL (Vaziri, 2003). These abnormalities are due to acquired hepatic LDL receptor and HDL docking receptor (SRB1) deficiencies as well as urinary excretion and reduced plasma concentration and enzymatic activity of lecithin cholesterol acyltransferase (LCAT) (Vaziri and Liang, 2002).

Niacin (nicotinic acid, vitamin B3) is a water-soluble vitamin that is critical for cellular metabolism (Maiese et al., 2009). It has been used successfully to regulate abnormalities in plasma lipid metabolism and is frequently referred to as a “broad spectrum anti-hyperlipidemic drug”. In pharmacological doses, niacin reduces total plasma cholesterol, triglyceride, VLDL, and LDL concentrations (Carlson, 1969; Figge et al., 1988). Niacin and its coenzymes NAD and Nicotinamide Adenine Dinucleotide Phosphate (NADP) have fundamental roles as a part of reduction/oxidation coenzymes involved in energy metabolism, amino acid metabolism, detoxification reactions for drugs and other substances as well as antioxidant protection (Permual et al., 2005). Many studies have examined the effects of niacin on various diseases such as anemia (Arun et al., 1999), hypertension (Cho et al., 2009), cardiovascular diseases (Brown et al., 2001) and liver diseases (Ganji et al., 2015). However, one of the roles through which niacin can have a potential effect on human health is that as an antioxidant, which has not been clearly investigated. However, there is no published information available on the pharmacokinetics of niacin in patients with renal disease. Although there is a lot of information available regarding the altered lipid metabolism in renal dysfunction but there is a gap with respect to the metabolic profile at different levels of cholesterol feeding and its interaction with niacin/nicotinic acid as such and also in renal dysfunction.

MATERIALS AND METHODS

The study was conducted in the Division of Veterinary Physiology and Biochemistry, faculty of Veterinary sciences and animal husbandry, Sher-e-kashmir University of Agricultural Sciences and Technology- Jammu, R.S. Pura, J&K, India.

Ethical approval

The animals were treated humanely during the whole period of experimental study and the work was approved.
Effect of cholesterol and niacin on renal dysfunction in rats

by the institutional Animal Ethics Committee vide No. 862/ac/04/CPCSEA on ethical standards in animal experimentation.

**Experimental material**

Specialized rat feed containing 3 levels of cholesterol supplementation @0%, 0.5% and 1% was procured from CSK HPKV, Palampur (H.P.), India. Diets were made equicalorie by supplementation with groundnut oil to match the energy content of the diet at three different cholesterol levels. Nicotinic Acid (as source of niacin) and all the other chemicals (analytical grade) used in the present study were procured from SD Fine-Chem Ltd., India and Sigma Aldrich Corporation, India. Gentamicin sulphate was procured from Genticyn company. Diagnostic Kits were procured from Erba diagnostics Mannheim.

**Experimental design**

The study was conducted on 84 adult healthy Wistar male rats with a mean body weight of 200±5gms. Animals were procured from Indian Institute of Integrative Medicine (IIIM), Council of Scientific & Industrial Research (CSIR,) Lab, Jammu. All the animals were provided standard pelleted ration and clean drinking water ad libitum. All the animals were maintained under standard managerial conditions. A daily cycle of 12 h of light and 12 h of darkness was provided to animals. Prior to start of experiment, the animals were acclimatized in the laboratory conditions for a period of more than 1 week. All the experimental animals were kept under constant observation during entire period of study. Study was carried out for a duration of sixty days excluding the time required for acclimatization of animals and induction of renal dysfunction. Prior to the start of the experiment renal dysfunction was induced in rats from (Group VII to group XII) by daily intra-peritoneal injection of gentamicin @ 80mg/kg body weight for 8 days. Niacin was supplemented in group II, group IV, group VI, group VIII, group X and group XII @ 100 mg/kg body weight for 60 days. Dose of niacin was selected as per Yanardag et al. (2005). Blood collection was made from retro-orbital fossa of all experimental rats on 0th day, 20th day, 40th day and 60th day of the experiment. Blood was collected and allowed to clot. This was followed by centrifugation at 3000 rpm for 15 minutes. The serum samples was collected and used to study enzymatic parameters. Estimation of serum AST, ALT, ALP and ACP were carried out using Erba diagnostic kits. Animals were slaughtered on 60th day of experiment and liver tissue was collected for histopathological analysis.

**Table 1: Group-wise treatment details of animals**

| Group | Clinical condition | Cholesterol supplementation | Niacin supplementation |
|-------|--------------------|-----------------------------|------------------------|
| I     | Kidney-Normal      | 0%                          | Un-supplemented        |
| II    | Kidney-Normal      | 0%                          | Supplemented           |
| III   | Kidney-Normal      | 0.5%                        | Un-supplemented        |
| IV    | Kidney-Normal      | 0.5%                        | Supplemented           |
| V     | Kidney-Normal      | 1.0%                        | Un-supplemented        |
| VI    | Kidney-Normal      | 1.0%                        | Supplemented           |
| VII   | Kidney-Compromised | 0%                          | Un-supplemented        |
| VIII  | Kidney-Compromised | 0%                          | Supplemented           |
| IX    | Kidney-Compromised | 0.5%                        | Un-supplemented        |
| X     | Kidney-Compromised | 0.5%                        | Supplemented           |
| XI    | Kidney-Compromised | 1.0%                        | Un-supplemented        |
| XII   | Kidney-Compromised | 1.0%                        | Supplemented           |

**Statistical analysis**

Statistical analysis was performed using generalized linear model analysis of variance (Snedecor and Cochran, 1994) and Duncan’s multiple range test (Duncan, 1955).

**RESULTS AND DISCUSSION**

The results are presented in the light of main effects and the interaction effects. The main effects are Kidney condition (K), Cholesterol level (C), Niacin supplementation (N) and Period of observation (P). The two way interaction effects studied are Kidney × Cholesterol (KC), Kidney × Niacin (KN), Kidney × Period (KP), Cholesterol × Niacin (CN), Cholesterol × Period (CP) and Niacin × Period (NP). The three way interaction effects studied are Kidney × Cholesterol × Niacin (KCN), Kidney × Cholesterol × Period (KCP) and Cholesterol × Niacin × Period (CNP).
× Period (KCP), Kidney × Niacin × Period (KNP), Cholesterol × Niacin × Period (CNP), four way interaction effects studied are Kidney × Cholesterol × Niacin × Period (KCNP).

Renal dysfunction as well as cholesterol supplementation resulted in significant (P<0.01) elevation of serum AST, ALT and ALP levels (Table 2). Increment with cholesterol supplementation was dose dependent. Niacin Supplementation @ 100 mg/kg body weight significantly (P<0.01) reduced serum AST. Significant (P<0.01) two, three and four way interactions between factors were also observed except for KN and KP. KNP interaction was also found to be significant (P<0.05) (Table 2). Significant (P<0.01) two and three-way interactions between factors were also observed except for KCN. KCNP interaction was also significant (P<0.05) (Table 2). Significant (P<0.01) two and three-way interactions between most of the factors were observed except for KCP and KCNP. KC interaction was also found to be significant (P<0.05) (Table 2). Renal dysfunction resulted in significant (P<0.01) reduction of serum ACP levels (Table 2). No significant effect of cholesterol and niacin supplementation were observed. Renal dysfunction resulted in significant (P<0.01) reduction of serum ACP levels. No significant effect of cholesterol and niacin supplementation were observed (Table 2). Also no interaction between factors in ACP were observed.

In present study renal dysfunction resulted in significant (P<0.01) elevation of serum enzymes AST, ALT and ALP levels. Serum levels of AST, ALT, ALP and ACP are the indicators of functional efficiency of liver and kidney (Alarifi et al., 2012). Similar findings have been documented in other studies also (Aboubakr and Abdelazem, 2016, Abbas et al., 2013). Gentamicin is reported to induce the production of ROS in the cells and the consequential damage to biological membrane. Therefore this elevation may be attributed to the release of these enzymes from the cell into the blood circulation after cellular damage and altered membrane permeability. The recorded increased level of ALT indicates functional disorders of the liver.

Fig. 1 (A): Photomicrograph of Liver of gentamicin toxic rats showing mononuclear cells infiltration (H&EX400), (B): Photomicrograph of Liver of 1% cholesterol fed rats showing anisocytosis (H&EX400), (C): Photomicrograph of Liver of gentamicin toxic rats along with niacin supplementation showing normal hepatocytes (H&EX100, (D): Photomicrograph of Liver of 1% cholesterol fed rats showing rats along with niacin supplementation showing normal architecture (H&EX100).
| Variables/Parameters | Kidney | Cholesterol Supplementation (% of diet) | Niacin Supplementation (mg/kg b.wt.) | Period Mean ± SEM | P value |
|----------------------|--------|----------------------------------------|--------------------------------------|------------------|---------|
|                      | Normal | Compromised                            | 0.0                                  | 0.5              | 1.0     | 0       | 100     |
| Aspartate aminotransferase (AST/SGOT; IU/L) |        |                                       |                                      |                  |         |         |         |
| 0th day              | 48.14  | 59.40                                  | 52.80                                | 53.91            | 54.59   | 54.12   | 53.42   | 53.77± 0.014 |
| 20th day             | 65.15  | 73.66                                  | 60.32                                | 71.01            | 76.89   | 77.18   | 61.64   | <0.01: K; C; N; P; KC; CN; CP; NP; KCN; KCP; CNP; KNP |
| 40th day             | 67.98  | 77.25                                  | 63.93                                | 75.78            | 78.13   | 87.38   | 57.85   | 1.894 72.61± 2.406 |
| 60th day             | 69.15  | 82.46                                  | 66.97                                | 79.69            | 80.76   | 95.02   | 56.60   | >0.05: KNP |
| Mean ± SEM           | 62.61± 0.998  | 73.19± 0.998                          | 61.01± 0.998                        | 70.10± 0.998     | 72.59± 0.998 | 78.42± 0.998 | 57.37± 0.998 | 67.90± 0.998 |
|                      | 1.68± 0.993  | 1.48± 0.993                           | 1.77± 0.993                         | 1.86± 0.993      | 2.192± 0.993 | 1.840± 0.993 | 0.810± 0.993 | 1.157± 0.993 |
| Alanine aminotransferase (ALT/SGPT; IU/L) |        |                                       |                                      |                  |         |         |         |
| 0th day              | 25.53  | 39.77                                  | 32.84                                | 31.10            | 34.00   | 33.19   | 32.11   | 32.65± 0.857 |
| 20th day             | 29.14  | 46.61                                  | 35.84                                | 38.44            | 39.34   | 41.61   | 34.13   | <0.01: K; C; N; P; KC; CN; CP; NP; KCN; KCP; CNP; KNP |
| 40th day             | 35.57  | 53.13                                  | 36.94                                | 42.54            | 53.57   | 52.39   | 36.31   | 1.326 44.35± 1.839 |
| 60th day             | 36.17  | 58.13                                  | 36.98                                | 45.31            | 59.17   | 58.46   | 35.85   | >0.05: KCNP |
| Mean ± SEM           | 31.60± 0.993  | 49.41± 0.993                          | 35.65± 0.993                        | 39.35± 0.993     | 46.52± 0.993 | 46.41± 0.993 | 34.60± 0.993 | 40.51± 0.993 |
|                      | 0.993± 0.993  | 1.071± 0.993                          | 1.255± 0.993                        | 1.550± 0.993     | 1.559± 0.993 | 1.468± 0.993 | 0.714± 0.993 | 0.876± 0.993 |
| Alkaline phosphatase (ALP; IU/L) |        |                                       |                                      |                  |         |         |         |
| 0th day              | 87.19  | 119.89                                 | 99.78                                | 106.58           | 104.26  | 102.45  | 104.64  | 103.54± 2.473 |
| 20th Day             | 93.39  | 109.55                                 | 94.95                                | 103.86           | 105.60  | 112.20  | 90.75   | <0.01: K; C; N; P; KC; CN; CP; NP; KCN; KCP; CNP; KNP |
| 40th day             | 98.28  | 108.05                                 | 101.40                               | 100.80           | 107.29  | 117.60  | 88.72   | 1.328 103.16± 2.232 |
| 60th day             | 110.86 | 119.75                                 | 101.82                               | 120.73           | 123.37  | 146.98  | 83.63   | <0.05: K |
| Mean ± SEM           | 97.43± 0.993  | 114.31± 0.993                         | 104.99± 0.993                       | 110.79± 0.993    | 119.81± 0.993 | 91.93± 0.993 | 105.87± 0.993 | 1.967± 0.993 |
| Acid phosphatase (ACP; IU/L) |        |                                       |                                      |                  |         |         |         |
| 0th day              | 0.72   | 0.66                                   | 0.69                                 | 0.68             | 0.70    | 0.71    | 0.67    | 0.69± 0.018 <0.05: K |
| 20th day             | 0.69   | 0.66                                   | 0.64                                 | 0.70             | 0.69    | 0.69    | 0.66    | 0.68± 0.014 >0.05: C; N; P; KC; KN; KP; CN; CP; NP; KCN; KCP; KNP; CNP; KNP |
| 40th day             | 0.69   | 0.65                                   | 0.66                                 | 0.69             | 0.65    | 0.65    | 0.69    | 0.67± 0.016 >0.05: C; N; P; KC; KN; KP; CN; CP; NP; KCN; KCP; KNP; CNP; KNP |
| 60th day             | 0.69   | 0.66                                   | 0.69                                 | 0.63             | 0.71    | 0.67    | 0.68    | 0.67± 0.014 >0.05: C; N; P; KC; KN; KP; CN; CP; NP; KCN; KCP; KNP; CNP; KNP |
| Mean ± SEM           | 0.70± 0.010  | 0.66± 0.012                           | 0.67± 0.013                         | 0.67± 0.014      | 0.69± 0.014 | 0.68± 0.011 | 0.68± 0.011 | 0.68± 0.008 |

*Means bearing different superscripts (abc) within a row of this column differ significantly. Means bearing different superscripts (ABC) within the column differ significantly. *Main effects (K: Kidney condition; C: cholesterol supplementation; N: Niacin supplementation; P: Period) and respective interaction effects.
kidney and heart (Mayne, 1994). Significant elevated levels of ALT and AST is usually concurred with renal damage (Smith et al., 1988). Kadkhoeae et al. (2005) has also shown a positive correlation between gentamicin induced acute renal dysfunction and elevated ALP levels. Nephrotoxin induced changes in ALP activity in proximal renal tubules has been reported (Taylor, 1965). ALP has been suggested as an early and sensitive index of nephrotoxicity and it could be used for diagnosing early renal tubular damage (Gyrd-Hansen, 1974). These facts are also supported by histopathological findings in hepatic tissue in gentamicin treated rats (Fig. A) as mononuclear cells infiltration in portal area was observed. A significant (P<0.01) reduction of serum ACP levels was also observed in our study under renal dysfunction. Sadava et al. (1996) has reported decreased activity of acid phosphatase in renal cortex as well as in renal medulla in progressive renal damage in rats. Decreased ACP activity in serum of chronic renal failure patients has been reported previously (Hasan and Abdul-Sattar, 2015). Decreased activity of ACP may be as a result of progressive impairment of phagocyte ability of neutrophils under renal dysfunction associated hyperureamia (Sharma et al., 2000).

Cholesterol supplementation in our study resulted in significant (P<0.01) elevation of serum AST, ALT and ALP levels. Our results are in agreement to the findings of Shanker and Debnath (2016). As AST, ALT and ALP are the marker enzymes of hepatotoxicity, our findings directly links the hepatotoxic activity of dietary cholesterol. High dietary cholesterol induced oxidative damage to liver must have resulted in release of these enzymes in the blood and their elevated levels (Ali, 2016). High cholesterol diets has been reported to increase lipid peroxidation in liver due to increased cholesterol accumulation in hepatocytes and lipotoxicity (Arguello et al., 2015). These facts are also supported by histopathological findings in hepatic tissue of cholesterol fed rats (Fig. B) as liver of cholesterol fed rats developed hepatic degeneration and anisocytosis. Nwozo et al. (2015) also documented similar findings in liver of hypercholesterolemic rats. Niacin supplementation @ 100 mg/kg body weight significantly (P<0.01) reduced serum levels of AST, ALT and ALP. Our results are also supported by our histopathological findings in which niacin supplementation resulted in improvement (Fig. C and D) in liver in gentamicin and 1% cholesterol fed group. Similar findings have been documented by De Paula et al. (2016). Antioxidant activity by inhibiting hepatic lipid accumulation of niacin may be credited to its hepatoprotective activity.

CONCLUSION
Niacin treatment of rats@ 100 mg/kg BW has resulted in significant normalization of enzyme levels in gentamicin and cholesterol fed rats.

ACKNOWLEDGEMENTS
The authors are highly thankful to Dean, Faculty of Veterinary and Animal Science SKUAST-J, R.S Pura Jammu for providing necessary facilities. The authors are greatful to Indian institute of Intergrated medicine, Council of scientific and industrial research Laboratory, Jammu for providing experimental rats. The trial was carried out at Division of Biochemistry, FVSc & AH, SKUAST-Jammu.

REFERENCES
Ali, R.F.M. 2016. Hypocholesterolemic effects of diets containing different levels of kishk as a dried fermented milkkewhole wheat mixture in experimental rats. *J. ethnic Foods*, 3: 117-123.
Arguello, G., Balboa, E., Arrese M. and Zanlungo, S. 2015. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. *Biochim. Biophys. Acta*, 1852 (9): 1765-177.
Alarifi, S., Al-Doaiss, A., Alkahtani, S., Al-Farraj, S.A., Al-Eissa, M.S., Al-Dahmash, B., Al-Yahya, H. and Mubarak, M. 2012. Blood chemical changes and renal histological alterations induced by gentamicin in rats. *Saudi J. Biol. Sci.*, 19: 103–110.
Abouabakr, M. and Abdelazem M. 2016. Hepatoprotective effect of aqueous extract of cardamom against gentamicin induced hepatic damage in rats. *Int. J. Sci. Basic. Appl. Res.*, 5 (1): 1-4.
Abbas, M.T., Zayni, M.M.H. and Al-Kadhi, N.A. 2013. Effect of Garlic Oil on Gentamicin Induced Hepatorenal Toxicity in rats. *Journal of Kerbala University*, 11 (2): 109-117.
Arun, K.G.P., Padmakumaran Nair, V., Manojkumar, K.V., Deependevi, L.R., Lakshmi, and P.A.
Kurup. 1999. Decreased hemolysis and lipid peroxidation in blood during storage in the presence of nicotinic acid. *Vox Sanguinis*, 76: 220–225, 1999.
Aslam, M., Dayal, R., Javed, K., Samim, M., Yadav, D., Zaidi, S. M.A. and Singh, S. 2013. 8-dehydroxy chrysophenol isolated from extract of rheum emodi enhance gentamicin induced nephrotoxicity in rats model. World J. Pharm. Pharm. Sci., 3(3): 833-849.

Carlson, L.A. 1969. The effect of nicotinic acid treatment on the chemical composition of plasma lipoprotein classes in man: drugs affecting lipid metabolism. Adv. Exp. Med. Biol., 4: 327-338.

Cho, K.H., Kim, H.J., Rodriguez-Iturbe, B. and Vaziri, N.D. 2009. Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure. Am. J. Physiol-Renal Physiol., 297: 106–113.

Brown, G., Albers, J.J., Fisher, L.D., Schaefer, S.M., Lin, J.T., Kaplan, C., Zhao, X.Q., Bisson, B.D., Fitzpatrick, V. F. and Dodge, H.T. 1990. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. New Eng. J. Med., 323:1289-1298.

Costa, S.V.L., Gil, F.Z. and Cavanal, M.F. 1987. Evaluation of distal tubules function in aminoglycoside induced nephropathy. Braz. J. Med. Biol. Res., 20: 833-836.

De Paula, E.S., Carneiroa, M.F.H., Grottob, D., Hernandez, L.C., Lusania Maria Greggi Antunesc, L. M. G. and Barbosa, F. 2016. Protective effects of niacin against methylmercury-induced genotoxicity and alterations in antioxidant status in rats. J. Toxicol. Environ. Health, 79(4): 174–183.

Duncan, D.B. 1955. Multiple range and multiple F-Tests. Biometrics, 11: 1-42.

Erdem, A., Gundogan, N.U., Usubutun, A., Kilinc, K., Erdem, S.R., Kara, A. and Bozkurt, A. 2000. The protective effect of taumine against gentamicin-induced acute tubular necrosis in rats. Nephrol. Dial. Transplant, 15(8): 1175-1182.

Figg, H.L., Figge, J., Souney, P.F., Mutnick, A.H. and Sacks, F. 1988. Nicotinic acid: a review of its clinical use in the treatment of lipid disorders. Pharmacother., 8: 287-294.

Ganj, S.H., Kashyap, M.L. and Kamanna, V.S. 2015. Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine il-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease. Metabolism, 64: 982-990.

Gyrd-Hansen, N. 1974. Alkaline phosphatase histochemistry and early renal cortical damage. Histochem. J., 6(2): 199–209.

Kadkhodaee, M. 2012. Erythropoietin; bright future and new hopes for an old drug. J. Nephro-pathol., 1(2): 81-82.

Hasan and Abdul-sattar. 2015. Evaluation of relationship between some biochemical parameters and osteodystrophy in patients with chronic renal failure. Int. J. Biochem. Biophys., 52: 239-247.

Homes, H.D. and Weinberg, J.M. 1986. Toxic nephropathies. In: Kidney. Brenner, BM, Rector FC Jr. (eds). Philadelphia, Saunders Co, 1491-533.

Kim, J.S., Ju, J.B., Choi, C.W. and Kim, S.C. 2006. Hypoglycemic and antihyperglycemic effect of Four Korean medicinal plants in alloxan induced diabetic Rats. Am. J. Biochem. Biotechnol., 2: 154-160.

Mahmood, D.H. and Waters, A. 1994. Comparative study of uranyl nitrate and cisplatin induced renal failure in rat. Eur. J. Drug. Metab. Pharmacokinet., 19(4): 327–336.

Maiese, K., Chong, Z.Z., Hou, J. and Shang, Y.C. 2009. The vitamin nicotinamide: translating nutrition into clinical care. Molecules, 14: 3446–3485.

Maye, P.D. 1994. Clinical Chemistry in Diagnosis and Treatment, sixth ed. Oxford University Press, Inc., New York, USA, p. 478. ISBN-13:978-0340576472.

Mori, Y. and Hirano, T. 2012. Ezetimibe alone or in combination with pitavastatin prevents kidney dysfunction in 5/6 nephrectomized rats fed highcholesterol. Metab., 61: 379-88.

Nwozo, S.O., Orojobi, B.F. and Adaramoye, O.A. 2015. Hypolipidemic and antioxidant potentials of Xylopia aethiopica seed extract in hypercholesterolemic rats. J. Med. Food, 14: 114-119.

Oda, H. and Keane, W.F. Recent advances in statins and the kidney. 1999. Kidney Int. Rep., 71: S2-S5.

Perumal, S.S., Shanthi, P. and Sachdanandam, P. 2005. Augmented efficacy of tamoxifen in rat breast tumorigenesis when gavaged along with riboflavin, niacin, and coq10: Effects on lipid peroxidation and antioxidantsin mitochondria. Chem. Biol. Interact., 152: 49–58.

Perazella, M.A. 2009. Renal vulnerability to drug toxicity. Clin. J. Am. Soc. Nephrol., 4(7): 1275–1283.

Sadava, D., Alonso, D., Hong, H. and Barrett, P.D. 1997. Effect of methadone addiction on glucose metabolism in rats. General Pharmacol., 28: 27–9.

Sharma, A., Tripathi, A.K., Kalra, O.P. and Chakarbart, A.K. 2000. Impaired functions of neutrophils in uremic patients. Natl. Med. J. India, 13: 121.

Shanker, N. and Debnath, S. 2016. Hypolipidemic Effect of Purslane (Portulaca oleracea L.) in Rats Fed on High Cholesterol Diet. J. Nutr. Food Sci., 6: 558.

Smith, R.L., Hill, L.R., Ilehman, R.J., Lefkwitz, P., Handler, A. and White. 1988. Principles of Biochemistry: Mammalian Biochemistry, seventh ed. McGraw-Hill, New York, USA.
Snedecor, G.W. and Cochran, W.G. 1994. Statistical Methods. 8th edn. The Iowa State University, Iowa (USA).

Stulak, J.M., Lerman, A., Caccitolo, J.A., Wilson, S.H., Romero, J.C., Schaff, H.V., Rodriguez-Porcel, M. and Lerman, L.O. 2001. Impaired renal vascular endothelial function in vitro in experimental hypercholesterolemia. Atheroscler., 154: 195-201.

Taylor, N.S. 1965. Histochemical studies of nephrotoxicity with sub-lethal doses of mercury in rats. Am. J. Pathol., 46: 1-21.

Vazquez-Perez, S., Aragoncillo, P., de Las Heras, N., Navarro-Cid, J., Cediel, E., Sanz-Rosa, D., Ruilope, L.M., Diaz, C., Hernandez, G., Lahera, V. and Cachofeiro, V. 2001. Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolemic rabbits. Nephrol. Dial. Transplant., 16: 40-44.

Vaziri, N.D. 2006. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am. J. Physio-Renal Physio., 290(2): F262-72.

Vaziri, N.D., Sato, T. and Liang, K. 2006. Molecular mechanism of altered cholesterol metabolism in focal glomerulosclerosis. Kidney Int., 63: 1756-1763.

Vaziri, N.D. and Liang, K. 2002. Upregulation of acyl-coenzyme A: cholesterol acyltransferase (ACAT) in nephrotic syndrome. Kidney Int., 61: 1769-1775.

Wilson, S.H., Chade, A.R., Feldstein, A., Sawamura, T., Napoli, C., Lerman, A. and Lerman, L.O. 2003. Lipid-lowering-independent effects of simvastatin on the kidney in experimental hypercholesterolemia. Nephrol. Dial. Transplant., 18: 703-709.

Yanardag, Peksel, R., Yesilyaprak, A., Doger, B. and Arsan-Atac, M.M.I. 2005. Effects of combination of niacin and chromium (III)-chloride on the skin and lungs of hyperlipidemic rats. Biol. Trace Elem. Res., 103: 249-260.